RESUMO
The aims of this research are: a) To compare GAF (Global Assessment of Functioning) score after the olanzapine treatment with the GAF score recorded after the treatment conducted by typical antipsychotics; b) To compare CGI (Global Clinical Impression) score after the treatment with CGI subsequent to treatment by typical antipsychotics; c) To compare number of hospitalizations of patients during the treatment with olanzapine with the number of hospitalizations during previous treatment; and 4. To monitor and record the possible weight gain of patients who were taking olanzapine. The research was conducted in the period from 2004 to 2007 in the Department of Psychiatry of the University Clinical Center in Sarajevo. Research subjects were patients with diagnosed schizophrenia who did not have expected response to the treatment with conventional antipsychotics, or who experienced serious adverse effects in the course of this treatment. Daily dosage of olanzapine was adjusted to the clinical condition of the patient and it varied from 5 to 20 mg a day. Clinical assessment is done once a month with CGI scale and GAF scale. During follow-up the possible weight gain was also followed. Statistically significant difference was found (p<0.001).